Price · last 3 months · daily close
TRMB price
Loading the price chart...
Daily closing prices via yfinance. Quotes are delayed. Past prices are not a guarantee of future results.
ValeriusBeta - Not investment advice
Research · S&P 500 · Information Technology
The numbers, the scorecard and what analysts say, with the source for each. Information, not advice.
Price · last 3 months · daily close
Loading the price chart...
Daily closing prices via yfinance. Quotes are delayed. Past prices are not a guarantee of future results.
Value Scorecard · run 2026-10-18
11 of the 12 checks that carry a score were scored from the data available. 1 could not be scored (Margin of Safety) and was left out, so the score is out of 55 instead of 60. The label uses the same share of the available points as for a full scorecard. The moat is shown as evidence from the filings, without a score.
Earnings & returns
Diluted EPS: $1.80 (2022), $1.25 (2023), $6.09 (2024), $1.76 (2025). It ended at or below 2022; the framework scores that as 2.
ROE (net income / common equity): 11.1% (2022), 6.9% (2023), 26.2% (2024), 7.3% (2025). Median 9.2%, lowest 6.9%; the framework scores a median 5-10% as 2.
ROIC of 7.6%: operating income of $592.00M divided by $7.81B of capital (total assets $9.31B minus current liabilities $1.50B), fiscal year to Jan 2, 2026, as filed in the 10-K (SEC EDGAR). The framework scores 5-10% as 2.
Net margin of -2.8%; the framework scores a negative net margin as 1; gross margin 71.8%, operating margin 15.1%.
Balance sheet & cash
Debt-to-equity of 0.29; the framework scores below 0.3 as 5 (total debt $1.46B, total cash $214.40M).
Free cash flow (operating cash flow minus capital expenditure): $348.00M (2022), $555.10M (2023), $497.80M (2024), $360.90M (2025). It ended above 2022 but did not rise in 2 of 3 years; the framework scores that as 3.
Retained earnings, as filed in the 10-Ks (SEC EDGAR): $2.23B (2022), $2.44B (2023), $3.76B (2025), $3.39B (2026). It rose every year but one and ended above 2022; the framework scores that as 4.
Valuation models
Trailing EPS is -$0.48; the Graham formula requires positive trailing EPS, so no intrinsic value is computed.
FCF/share = $2.943, stage 1 growth = 0.0% (revenue CAGR -2.8% floored at 0%; the company is valued as if it does not grow rather than extrapolating the decline) for 5 years, terminal growth = 3%, discount rate = 10%. Stage 1 PV = $11.16, PV of terminal value = $26.89, DCF value = $38.04. Current price $59.46; price is 56.3% above the model value.
Needs both a Graham value and a DCF value. Graham value N/A (not comparable); DCF value $38.04 (price is 56.3% above the model value).
P/B of 2.71; the framework scores 1.5-3.0 as 3.
Business quality
A moat (a brand, a network, switching costs, patents, scale, a licence) is not a number in the filings, so Valerius doesn’t score it. Below are the figures and the words moat analysis starts from, from the company’s own 10-K filings. The conclusion is yours.
Return on capital, each year
Above 15% in 0 of 10 years (2016-2026); lowest 5.8%, highest 9.5%.
Gross margin, each year
Between 52.1% and 69.1% over 10 years (a range of 17.0 points).
Competition, in the company’s own words · 10-K filed Feb 25, 2026
The latest 10-K has no section headed “Competition” that could be quoted. Open the filing to read how the company describes its markets.
Return on capital = operating income / (total assets − current liabilities), the ROIC row’s definition; 15% is the framework’s return threshold. Gross margin = gross profit / revenue. Both from each year’s 10-K via SEC EDGAR. Moat analysis commonly looks at whether returns and margins held up over many years. These figures don’t say whether the company has an advantage, what it is, or whether it will last.
Capital allocation, 2022-2025: dividends or buybacks paid in every year (pass); $1.55B paid out against $1.76B of free cash flow (pass); total debt $1.63B to $1.39B, down 14.3%, 1.8x EBITDA (pass: not up more than 10%); shares outstanding 0.25B to 0.24B, down 4.4% (pass). 4 of 4 tests passed; the framework scores that as 5.
Filings
Three kinds of event the company reported to the SEC in the last 5 years, from its filings on SEC EDGAR.
Loading...
These are events the company reported to the SEC. An auditor change or a late filing can have many causes; each date links to the filing, where the company explains it. Valerius does not score these.
Graham Formula:
Trailing EPS -$0.48 — formula requires positive trailing EPS, no value computed.
DCF:
FCF/share = $2.943
Stage 1 growth = 0.0% for 5 years | terminal growth = 3.0% | discount rate = 10.0%
Stage 1 g floored at 0.0% (3-year revenue CAGR was -2.8%; the company is valued as if it does not grow rather than extrapolating the decline)
Y1: $2.943 → PV $2.675
Y2: $2.943 → PV $2.432
Y3: $2.943 → PV $2.211
Y4: $2.943 → PV $2.010
Y5: $2.943 → PV $1.827
Stage 1 PV sum = $11.16
Terminal value at end of Y5 = $43.30
PV of terminal value = $26.89
DCF value = $38.04
Current price $59.46 vs DCF value $38.04 — price is 56.3% above the model value.Data from yfinance summary figures and financial statements, and from the company’s 10-K filings via SEC EDGAR; computed at a price of $59.46. Every score is calculated from the figures by the framework’s fixed rules, and the explanation beside it is generated from the same figures: Graham value, DCF value, margin of safety, ROIC, profit margins, debt-to-equity, price-to-book, EPS trend, ROE trend, free cash flow, retained earnings and capital allocation. No AI is involved in this scorecard. The moat is shown as evidence, without a score. Read each score with the figures beside it. A check that cannot be scored from the available data is shown as not scored and left out of the composite score. Intrinsic value calculations are model outputs based on stated assumptions, not predictions.
Recent headlines · third-party publishers · not investment advice
The 8 newest headlines whose title names the company, shown automatically and never chosen by Valerius. From third-party publishers via Yahoo Finance, linked to the source. Valerius doesn't write or endorse them. Not investment advice.